Skip to main content

Table 2 Abstinence rates and odds ratios by treatment condition

From: Flexible, dual-form nicotine replacement therapy or varenicline in comparison with nicotine patch for smoking cessation: a randomized controlled trial

 

NRT

NRT+

VR

Primary outcome: continuous abstinence at week 5–52

 Abstinence, n (%)

23 (10)

29 (12.4)

36 (15.3)

 OR (97.5 % CI)

REF

1.28 (0.67–2.43)

1.62 (0.87–3.01)

 Unadjusted

 Adjusted

REF

1.34 (0.67–2.70)

1.84 (0.94–3.58)

Secondary outcome: 7-day point prevalence abstinence at week 52

 n (%)

34 (14.8)

43 (18.5)

51 (21.7)

 Unadjusted

REF

1.31 (0.76–2.25)

1.60 (0.94–2.70)

 Adjusted

REF

1.31 (0.79–2.37)

1.84 (1.04–3.26)*

Secondary outcome: continuous abstinence at week 5–22

 n (%)

38 (15.8)

59 (24.5)

65 (27.1)

 Unadjusted

REF

1.51 (0.88–2.57)

2.01 (1.20–3.36)**

 Adjusted

REF

1.67 (0.95–2.94)

2.18 (1.25–3.80)**

Secondary outcome: 7-day point prevalence at week 22

 n (%)

38 (15.8)

59 (24.5)

65 (27.1)

 Unadjusted

REF

1.72 (1.04–2.85)*

1.96 (1.20–3.23)**

 Adjusted

REF

1.87 (1.09–3.20)*

2.09 (1.22–3.57)**

Secondary outcome: continuous abstinence week 5–10

 n (%)

72 (29.4)

94 (38.7)

98 (39.8)

 Unadjusted

REF

1.52 (1.00–2.30)

1.58 (1.04–2.39)*

 Adjusted

REF

1.62 (1.03–2.56)*

1.66 (1.04–2.63)*

Secondary outcome: 7-day point prevalence at week 10

 n (%)

65 (26.5)

88 (36.2)

97 (39.4)

 Unadjusted

REF

1.57 (1.03–2.41)*

1.79 (1.17–2.73)**

 Adjusted

REF

1.65 (1.04–2.61)*

1.89 (1.19–3.01)**

  1. REF, reference group; OR, odds ration; 97.5 % CI, 97.5 % confidence interval; NRT, standard dose, nicotine replacement therapy; NRT+, flexible, dual-form nicotine replacement therapy; VR, varenicline
  2. Adjusted for marital status, income, nicotine dependence, psychiatric status and motivation to quit. *P < 0.025; **P < 0.01